![]() |
|
|
Vol. 294, Issue 1, 204-209, July 2000
Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky
| |
Abstract |
|---|
|
|
|---|
Recent studies have suggested that cell migratory responses are often mediated by Gi protein-coupled receptors. Because it is known that CB1 cannabinoid receptors are coupled to pertussis toxin-sensitive G proteins, we proposed that CB1 may mediate cell migration. To test this hypothesis, modified Boyden chamber assays were used to investigate cell migration mediated by CB1 cannabinoid receptors. HU-210, WIN55212-2, and anandamide, three cannabinoid agonists with distinct chemical structures, induced migration of human embryonic kidney 293 cells stably transfected with human CB1 gene, but not 293 cells transfected with an empty expression vector. These migratory responses were concentration-dependent. The EC50 values for HU-210, WIN55212-2, and anandamide were 0.19 ± 0.04, 12.2 ± 1.4, and 39.9 ± 3.7 nM, respectively. The maximal migration index for HU-210, WIN55212-2, and anandamide were 8.9 ± 1.6, 9.5 ± 1.6, and 8.8 ± 1.3, respectively. Pretreating cells with 100 ng/ml pertussis toxin eliminated the cannabinoid agonist-induced cell migration. SR141716A, a selective antagonist for CB1, inhibited the cannabinoid agonist-induced migratory responses in a concentration-dependent manner. Checkerboard analysis demonstrated that anandamide-induced cell migrations are due to chemotaxis as well as chemokinesis. Furthermore, anandamide-induced migratory responses were inhibited, in a concentration-dependent manner, by PD098059, an inhibitor of mitogen-activated protein kinase activation, but not by 8-bromoadenosine-3',5'-cyclic monophosphate, a cell-permeable cAMP analog. These data demonstrate that cannabinoid agonists are able to induce chemotaxis and chemokinesis, and that these migratory responses are mediated by G protein-coupled, CB1 cannabinoid receptors. In addition, these data suggest that activation of mitogen-activated protein kinase plays an important role, whereas inhibition of adenylate cyclase is probably not involved in the cell migration mediated by CB1.
| |
Introduction |
|---|
|
|
|---|
Since
the initial description that
9-tetrahydrocannabinol, the active constituent
of marijuana, interacts with a specific G protein-coupled receptor
(Howlett et al., 1986
; Devane et al., 1988
), two subtypes of
cannabinoid receptors, known as CB1 and CB2, have been cloned and
identified (Matsuda et al., 1990
; Munro et al., 1993
). CB1 is
distributed in the central nervous system (Herkenham et al., 1991
;
Matsuda et al., 1993
), as well as several peripheral tissues, including
testis and immune cells (Gerard et al., 1991
; Bouaboula et al., 1993
).
Using cells that express native cannabinoid receptors and cell lines
transfected with cloned cannabinoid receptors, previous studies have
demonstrated that CB1 is coupled to pertussis toxin-sensitive G
proteins (Howlett et al., 1986
; Felder et al., 1992
). The known
downstream signal transduction pathways of CB1 include inhibition of
adenylate cyclase (Howlett et al., 1986
; Felder et al., 1992
),
activation of mitogen-activated protein kinase (MAPK) (Bouaboula et
al., 1995
), and modulation of ion channels (Mackie and Hille, 1992
).
Cell migration plays important roles in many physiological and
pathological processes, including embryogenesis, angiogenesis, metastasis, inflammation, and wound healing (Lauffenburger and Horwitz,
1996
). Many chemoattractants are ligands for G protein-coupled receptors. Pertussis toxin-sensitive G proteins are thought to be
crucial for the cell migration mediated by chemokine receptors (Gerard
and Gerard, 1996
). Recent studies have suggested that the ability to
mediate cell migration may be shared by many receptors that are coupled
to Gi proteins (Arai et al., 1997
; Neptune and Bourne, 1997
). Because it is known that CB1 is coupled to pertussis toxin-sensitive G proteins, we postulated CB1 may mediate cell migratory responses. To test this hypothesis, the abilities of cannabinoid agonists to induce cell migration were examined in human
embryonic kidney 293 cells stably transfected with human CB1
gene. Cell migration can be classified into three categories: 1)
random, 2) chemokinesis, and 3) chemotaxis (Lauffenburger and Horwitz,
1996
; Mitchison and Cramer, 1996
). Random migrations of cells
occur in the absence of a stimulus. Chemokinesis is random motion that
is affected by a chemical stimulus. Chemotaxis is directed motion of
cells toward a gradient of a chemical stimulus. In this study,
checkerboard analysis was performed to study whether the cannabinoid
agonist-induced cell migration is due to either chemokinesis or
chemotaxis. Currently, the cellular and molecular mechanisms for cell
migration have not been completely understood. It is generally believed
that Gi proteins are important in mediating cell
migration (Gerard and Gerard, 1996
; Arai et al., 1997
; Neptune and
Bourne, 1997
). However, it is not clear which downstream targets of
Gi proteins are crucial in cell migration. In
this study, the involvement of G protein-coupled CB1 in cell migration
was examined with pertussis toxin and with a selective CB1 antagonist.
Furthermore, the roles of adenylate cyclase inhibition and MAPK
activation, two known signal transduction pathways for CB1, were
investigated using a cell-permeable analog of cAMP and an inhibitor of
MAPK activation.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials. Adenovirus-transformed 293 cells were obtained from American Type Culture Collection (Rockville, MD). Tissue culture reagents were purchased from Biowhittaker (Walkersville, MD). WIN55212-2, anandamide, and SR141716A were obtained from RBI (Natick, MA). HU-210 was purchased from Tocris (Balwin, MO). The stock solutions of cannabinoids were made by dissolving cannabinoids in dimethyl sulfoxide. BSA, mouse collagen type I, pertussis toxin, 8-bromoadenosine 3',5'-cyclic monophosphate (8-Br-cAMP), and PD098059 were purchased from Sigma (St. Louis, MO). The 48-well modified Boyden chamber and polycarbonate membranes with 10-µm pore size were purchased from Neuro Probe Inc. (Bethesda, MD).
Cell Culture.
Human embryonic kidney 293 cells stably
transfected with human CB1 gene were used (Song and Bonner,
1996
). The CB1 cannabinoid receptors expressed in these cells have a
Bmax value of 1217.6 ± 221.9 fmol/mg of protein. It has been shown that these cells do not express
CB2, and the CB1 expressed in these cells are functional (Song and
Bonner, 1996
). The 293 cell system is an appropriate model system for
studying the roles of G protein-coupled receptors in cell migration.
This has been shown by other investigators with known inducers of
migration, e.g., interleukin-8 receptors (Neptune and Bourne,
1997
). Cells were maintained in Dulbecco's modified Eagle's medium
(DMEM) supplemented with 10% fetal calf serum, 100 U/ml penicillin,
100 µg/ml streptomycin, and 20 mM L-glutamine.
Cells were grown at 37°C in a humidified 5%
CO2 incubator.
Cell Migration Assays.
In vitro cell migration assays were
performed using a modified 48-well Boyden chamber as described
previously (Falk et al., 1980
). Briefly, cells were washed twice with
PBS and harvested from the culture dish into a 50-ml centrifuge tube
with EDTA-trypsin (Biowhittaker). Subsequently, the cells were washed
with DMEM supplemented with 0.2% BSA, centrifuged at 500g,
and cell pellets were resuspended in the same medium with a final cell
concentration of 1.0 × 106 cell/ml.
Chemoattractant solutions were made by diluting cannabinoid agonists in
DMEM supplemented with 0.2% BSA. Polycarbonate membranes (polyvinylpyrrolidone-free, pore size 10.0 µm) were coated overnight at 4°C with 50 µg/ml mouse collagen type I. After loading
chemoattractant solutions in the lower chamber, a sheet of
polycarbonate membrane was placed on top of the chemoattractant
solution, the upper chamber was properly assembled, and aliquots of
50-µl cell suspensions were placed in the upper chamber. The
chamber was incubated for 5 h in a 37°C incubator with
humidified air and 5% CO2. At the end of the
incubation period, the polycarbonate membrane was removed, nonmigrated
cells were carefully removed by scraping against a wiper, and the
membrane was stained with a HEMA 3 staining kit (Fisher Scientific
Inc., Houston, TX). For each well in the Boyden chamber, the number of
cells migrating through to the underside of the membrane was counted in
six nonoverlapping low power field (×100) using a light microscope
equipped with an ocular micrometer. The results were expressed as a
migration index, which was defined as: mean number of cells per low
power field for test substances/mean number of cells per low power
field for medium control (DMEM supplemented with 0.2% BSA).
Experiments were performed in triplicate and were repeated three times.
Checkerboard Analysis.
Chemical-induced increases in cell
mobility could be attributed to either chemotaxis or chemokinesis. To
distinguish chemotaxis from chemokinesis, checkerboard assays were
performed (Zigmond and Hirsch, 1973
; Wilkinson, 1998
). Briefly, various
concentrations of anandamide, an endogenous cannabinoid agonist, were
placed in upper wells, lower wells, or both upper and lower wells of the chemotaxis chamber to determine whether the number of migrated cells was greater with a positive gradient, no gradient, or a negative
gradient of anandamide. According to the definition of chemotaxis and
chemokinesis, cell migration toward a positive gradient represents
chemotaxis, whereas drug-stimulated random cell migration (toward no
gradient or a negative gradient) represents chemokinesis.
Cell Pretreatment. To study the involvement of pertussis toxin-sensitive G proteins, cells were pretreated for 16 h with 100 ng/ml pertussis toxin in DMEM medium containing 10% fetal calf serum, 100 U/ml penicillin, 100 µg/ml streptomycin, and 20 mM L-glutamine at 37°C, 95% air, 5% CO2. The cells were washed and resuspended after pertussis toxin treatment. To study the effects of CB1 antagonist SR141716A, cell-permeable cAMP analog 8-Br-cAMP, and MAPK activation inhibitor PD098059, cell suspensions were pretreated with these agents for 30 min in DMEM supplemented with 0.2% BSA before being subjected to cell migration assays.
Data Analysis. The data presented in the table and figures represent mean ± S.E. The data were analyzed and the concentration-response curves were generated with the use of GraphPad Prizm software. The EC50 and maximal migration index values were determined through nonlinear regression analysis performed with GraphPad Prizm. One-way or two-way ANOVA was used to compare the data of different treatment groups. The level of significance was chosen as P < .05.
| |
Results |
|---|
|
|
|---|
Effects of Cannabinoid Agonists on Cell Migration.
HU-210,
WIN55212-2, and anandamide, three cannabinoid agonists that belong to
three different chemical classes (Mechoulam et al., 1988
; Compton et
al., 1992
; Devane et al., 1992
), increased the migration of 293 cells
stably transfected with human CB1 gene from the upper
chamber to the underside of the membrane (Fig. 1). The effects of cannabinoid agonists
on cell migration were concentration-dependent (P < .05 by ANOVA). The EC50 values for HU-210,
WIN55212-2, and anandamide were 0.19 ± 0.04, 12.2 ± 1.4, and 39.9 ± 3.7 nM, respectively. Approximately 30 to 50 cells migrated in the absence of drugs. The maximal migration index values
for HU-210, WIN55212-2, and anandamide were 8.9 ± 1.6, 9.5 ± 1.6, and 8.8 ± 1.3, respectively. In contrast, cannabinoid agonists did not affect the migration of 293 cells transfected with an
empty RC/CMV expression (P > .05 by ANOVA)
(Fig. 1).
|
Effects of Pertussis Toxin on Cannabinoid Agonist-Induced Cell Migration. To study the involvement of pertussis toxin-sensitive G proteins in cannabinoid agonist-induced cell migration, cells were pretreated with 100 ng/ml pertussis toxin for 16 h. As demonstrated in Fig. 1, pretreatment of cells with pertussis toxin blocked the cell migration induced by HU-210, WIN55212-2, and anandamide (P < .05 by two-way ANOVA). Pertussis toxin pretreatment at the same concentration was able to block cannabinoid-induced inhibition of forskolin-stimulated cAMP accumulation (data not shown).
Effects of a CB1 Antagonist on Cannabinoid Agonist-Induced Cell
Migration.
SR141716A, a selective CB1 antagonist (Rinaldi-Carmona
et al., 1994
), was used to test whether cannabinoid agonist-induced cell migration is mediated by specific CB1 receptors. In a
concentration-dependent manner, SR141716A inhibited the cell migration
induced by HU-210, WIN55212-2, and anandamide. The
concentration-response curves were shifted parallel to the right by
SR141716A (P < .05 by two-way ANOVA) (Fig. 2,
A, B, and C). The
pA2 values for SR141716A against HU-210,
WIN55212-2, and anandamide were 7.81 ± 0.20, 8.09 ± 0.04, and 7.92 ± 0.02, respectively. SR141716A by itself had no
significant effect on the cell migration (Fig. 2D).
|
Checkerboard Analysis of Anandamide-Induced Cell Migration.
Checkerboard analysis was performed to examine the degree to which the
migratory responses of cells are due to chemotactic or chemokinetic
effects (Wilkinson, 1998
; Zigmond and Hirsch, 1973
). The results
of checkerboard analysis are shown in Table 1. The underlined values along the
diagonal reflect migratory responses to uniform concentrations of
anandamide on both sides of the chamber (chemokinesis). The values
below the diagonal reflect responses to a positive gradient
(chemotaxis), whereas the values above the diagonal represent responses
to a negative gradient (chemokinesis). When equal concentrations of
anandamide were present in the upper and lower chambers, the migration
indexes were increased with increasing concentrations of anandamide
(P < .05 by ANOVA). The migration indexes were
increased with an increase in positive gradient of anandamide
(P < .05 by ANOVA). These data demonstrate that
anandamide induced both chemokinesis and chemotaxis, with chemotaxis
stimulated to a greater extent (maximum of 7.79/1.12 = 7-fold
increase over the background compared with a 5.54/1.12 = 5-fold
increase for chemokinesis).
|
Effects of a Cell-Permeable Analog of cAMP on Anandamide-Induced
Cell Migration.
To study whether the anandamide-induced cell
migration is a result of inhibition of adenylate cyclase, thereby a
decrease in intracellular cAMP levels, the cells were pretreated with
8-Br-cAMP for 30 min before being subject to migration assays. As shown in Fig. 3A, this pretreatment did not
block the migratory responses induced by anandamide. At 1 and 3 mM,
8-Br-cAMP might have enhanced cell migration. However, analysis
by ANOVA demonstrated no significant differences (P > .05) between the data points in Fig. 3A. In the absence of
cannabinoids, 8-Br-cAMP by itself had no significant effect
(P > .05 by ANOVA) on the cell migration (Fig. 3B). In our control experiments, 8-Br-cAMP was active in that it enhanced the
activation of MAPK by cannabinoids as previously demonstrated (Bouaboula et al., 1995
) (data not shown).
|
Effects of an Inhibitor of MAPK Activation on
Anandamide-Induced Cell Migration.
MAPK, i.e., extracellular
signal-regulated kinase (ERK)-1 and ERK-2, are a group of
serine/threonine-specific protein kinases that are activated by various
cell surface receptors, including receptor tyrosine kinases, receptors
coupled to cytoplasmic tyrosine kinases, and G protein-coupled
receptors (Hill and Treisman, 1995
; Seger and Krebs, 1995
). PD98059 is
an inhibitor of MEK (MAPK or ERK kinase), a dual specific kinase
that activates both ERK-1 and ERK-2 by phosphorylation at specific
threonine and tyrosine residues (Alessi et al., 1995
). PD098059 was
used to study the role of MAPK activation in anandamide-induced cell
migration. In a concentration-dependent manner, PD098059 inhibited the
anandamide-induced cell migration, with an IC50
value of 8.6 ± 1.3 µM (Fig. 4A)
(P < .05 by ANOVA). In the absence of cannabinoids,
PD098059 by itself had no significant effect on the cell migration
(Fig. 4B) (P > .05 by ANOVA). In our control
experiments, PD098059 was able to inhibit cannabinoid-induced MAPK
activity as expected (Alessi et al., 1995
) (data not shown).
|
| |
Discussion |
|---|
|
|
|---|
In this study, HU-210, WIN55212-2, and anandamide, three cannabinoid agonists with distinct chemical structures, were found to cause the migration of 293 cells stably transfected with human CB1 gene. In contrast, these cannabinoid agonists did not cause the migration of 293 cells stably transfected with an empty expression vector. The cannabinoid-induced cell migrations were concentration-dependent, with a rank order of potency of HU-210 > WIN55212-2 > anandamide. The concentration-response curves of cannabinoid agonists were shifted parallel to the right by SR141716A, a selective antagonist for CB1. These data indicate that the cannabinoid agonist-induced cell migratory responses are mediated by specific CB1 receptors expressed in these cells.
The cannabinoid-induced migratory responses were impaired in this study
by pretreatment of cells with 100 ng/ml pertussis toxin. These results
demonstrate that pertussis toxin-sensitive G proteins are crucial for
cannabinoid agonist-induced cell migration. These results are
consistent with the previous reports that functional CB1s are
coupled to Gi proteins (Howlett et al., 1986
;
Felder et al., 1992
). These data also support the notion suggested by Arai et al. (1997)
and Neptune and Bourne (1997)
that the ability to
mediate cell migration is shared by Gi-coupled receptors.
To identify the type of cell migration induced by anandamide, checkerboard analyses were carried out in this study. Our experiments demonstrated that anandamide is able to induce both chemotaxis and chemokinesis; however, chemotaxis was induced to a greater extent.
One of the known mechanisms of signal transduction for CB1 is
inhibition of adenylate cyclase (Howlett et al., 1986
; Felder et al.,
1992
). However, in this study we found 8-Br-cAMP, a cell-permeable analog of cAMP, did not attenuate cannabinoid agonist-induced cell
migration. These results indicate that cell migration is not mediated
by a decrease of intracellular cAMP level induced by anandamide. This
conclusion is consistent with the previous findings that cAMP is not a
critical intracellular mediator of cell migration (Neptune and Bourne,
1997
).
The well known roles of MAPK are their involvement in the signal
transduction between the plasma membrane receptors and the nucleus
(Hill and Treisman, 1995
; Seger and Krebs, 1995
). For Gi protein-coupled receptors, it has been shown
that the activation of MAPK pathway is mediated by 
subunit
stimulation of Ras (Crespo et al., 1994
; Koch et al., 1994
). However,
in certain cell types, Gi proteins use a novel

- and Ras-independent pathway to activate MAPK (Hedin et al.,
1999
). At present, the roles of MAPK in cell migratory responses
mediated by G protein-coupled receptors have not been established, and
existing reports are controversial. For example, Kuroki and O'Flaherty
(1997)
reported that PD098059 blocks neutrophil chemotaxis induced by
several chemoattractants. In contrast, Knall et al. (1997)
reported
that MAPK activation is not important in interleukin-8-induced
chemotaxis. It has been established that activation of CB1 cannabinoid
receptor increases the activity of MAPK (Bouaboula et al., 1995
). In
this study, PD098059 inhibited concentration dependently
anandamide-induced cell migration. The effective concentrations of
PD098059 in inhibiting cell migration are within the concentration
range for this drug to inhibit MAPK activation (Alessi et al., 1995
).
Thus, these data suggest that activation of MAPK may play an important
role in anandamide-induced cell migration. Currently, it is not clear how the MAPK activation is involved in anandamide-induced cell migration. Cytoskeletal regulation is a critical step in cell migration
(Lauffenburger and Horwitz, 1996
; Mitchison and Cramer, 1996
). MAPK has
been reported to regulate cytoskeleton and cell motility by
phosphorylating and enhancing myosin light chain kinase activity
(Klemke et al., 1997
). Because it is known that anandamide can activate
MAPK (Wartmann et al., 1995
), one possible mechanism for
anandamide-induced cell migration may be anandamide-induced activation
of MAPK, and subsequent cytoskeletal regulation by MAPK. In this study,
the inhibition by PD098058 was not complete. This suggests that in
addition to MAPK, there might be other pathways that are involved in
cannabinoid-induced cell migration.
After demonstrating the involvement of CB1 in cannabinoid-induced migration with three different agonists, we focused on anandamide because it is an endogenous cannabinoid agonist. We expect similar mechanisms for HU-210 and WIN55212-2 because it is well known that both of these ligands activate similar second messenger systems through CB1.
In summary, to our knowledge this is the first report that cannabinoid agonists can induce cell migration. These migratory responses are concentration-dependent, antagonized by SR141716A, a selective antagonist for the CB1, and blocked by pertussis toxin pretreatment. These results indicate that these migratory responses are mediated by G protein-coupled, CB1 cannabinoid receptors. Furthermore, anandamide-induced migratory responses are blocked by PD098059, an inhibitor of MAPK activation, but not by 8-Br-cAMP, a cell-permeable analog of cAMP. These data suggest that activation of MAPK, but not inhibition of adenylate cyclase, are crucial for the cell migration mediated by CB1. The detailed cellular and molecular mechanisms underlying the CB1-mediated cell migratory responses warrant additional investigation.
| |
Footnotes |
|---|
Accepted for publication March 22, 2000.
Received for publication November 15, 1999.
1 This work was supported in part by National Institutes of Health Grant DA-11551.
Send reprint requests to: Z. H. Song, Ph.D., Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40292. E-mail: zhsong{at}louisville.edu
| |
Abbreviations |
|---|
MAPK, mitogen-activated protein kinase; 8-Br-cAMP, 8-bromoadenosine-3',5'-cyclic monophosphate; DMEM, Dulbecco's modified Eagle's medium; ERK, extracellular signal-regulated kinase.
| |
References |
|---|
|
|
|---|

dimers released by activation of Gi-coupled receptors.
Proc Natl Acad Sci USA
94:
14495-14499
subunits.
Nature (Lond)
369:
418-420[Medline].
- and Ras-independent pathway to activate extracellular signal-regulated kinase and mobilize AP-1 transcription factors in Jurkat T lymphocytes.
J Biol Chem
274:
19992-20001
activation of p21ras.
Proc Natl Acad Sci USA
91:
12706-12710
subunit of Gi, not by activating Gq or Gs.
Proc Natl Acad Sci USA
94:
14489-14494This article has been cited by other articles:
![]() |
A. I. Chernyavsky, J. Arredondo, L. M. Marubio, and S. A. Grando Differential regulation of keratinocyte chemokinesis and chemotaxis through distinct nicotinic receptor subtypes J. Cell Sci., November 1, 2004; 117(23): 5665 - 5679. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Franklin, S. Parmentier-Batteur, L. Walter, D. A. Greenberg, and N. Stella Palmitoylethanolamide Increases after Focal Cerebral Ischemia and Potentiates Microglial Cell Motility J. Neurosci., August 27, 2003; 23(21): 7767 - 7775. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||